CO2018009205A2 - Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna - Google Patents

Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna

Info

Publication number
CO2018009205A2
CO2018009205A2 CONC2018/0009205A CO2018009205A CO2018009205A2 CO 2018009205 A2 CO2018009205 A2 CO 2018009205A2 CO 2018009205 A CO2018009205 A CO 2018009205A CO 2018009205 A2 CO2018009205 A2 CO 2018009205A2
Authority
CO
Colombia
Prior art keywords
vaccine
composition
treating cancer
skin lesion
cell carcinoma
Prior art date
Application number
CONC2018/0009205A
Other languages
English (en)
Spanish (es)
Inventor
Tim Ioannides
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of CO2018009205A2 publication Critical patent/CO2018009205A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CONC2018/0009205A 2016-02-27 2017-02-24 Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna CO2018009205A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
CO2018009205A2 true CO2018009205A2 (es) 2018-09-20

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0009205A CO2018009205A2 (es) 2016-02-27 2017-02-24 Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna

Country Status (16)

Country Link
EP (1) EP3419661A4 (https=)
JP (3) JP2019506435A (https=)
KR (1) KR102873848B1 (https=)
CN (1) CN108883168A (https=)
AU (1) AU2017223970B2 (https=)
BR (1) BR112018067550A2 (https=)
CA (1) CA3015519A1 (https=)
CL (1) CL2018002438A1 (https=)
CO (1) CO2018009205A2 (https=)
HK (1) HK1256935A1 (https=)
IL (1) IL261340B2 (https=)
MX (1) MX2018010338A (https=)
MY (1) MY194694A (https=)
SG (1) SG11201807080UA (https=)
WO (1) WO2017147475A1 (https=)
ZA (1) ZA201805679B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
PL4225351T1 (pl) * 2020-10-12 2023-12-11 Hpvvax, Llc Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym
WO2024097051A1 (en) * 2022-10-31 2024-05-10 Pyrojas Inc. Immunotherapy compositions and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP3427755B1 (en) * 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
SG177269A1 (en) * 2009-06-25 2012-02-28 Glaxosmithkline Biolog Sa Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) * 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine
JP7037884B2 (ja) * 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
EP3419661A4 (en) 2019-10-23
KR102873848B1 (ko) 2025-10-17
JP2023110038A (ja) 2023-08-08
BR112018067550A2 (pt) 2019-10-01
AU2017223970B2 (en) 2022-01-27
EP3419661A1 (en) 2019-01-02
JP2019506435A (ja) 2019-03-07
MY194694A (en) 2022-12-15
JP2021155448A (ja) 2021-10-07
MX2018010338A (es) 2018-11-09
HK1256935A1 (zh) 2019-10-04
ZA201805679B (en) 2019-11-27
AU2017223970A1 (en) 2018-09-13
WO2017147475A1 (en) 2017-08-31
CL2018002438A1 (es) 2019-01-04
JP7732784B2 (ja) 2025-09-02
KR20180112043A (ko) 2018-10-11
CA3015519A1 (en) 2017-08-31
CN108883168A (zh) 2018-11-23
IL261340A (en) 2018-11-29
IL261340B2 (en) 2023-07-01
SG11201807080UA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
HK1246183A1 (zh) Hpv疫苗
CL2019003091A1 (es) Terapia de combinación.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MX2019008063A (es) 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
CL2025001937A1 (es) Arn terapéutico para el cáncer positivo para vph
CL2024001738A1 (es) Vacunas peptídicas
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016007726A (es) Inmunoterapia de cancer mediante el suministro de antigenos mhc clase ii usando un replicon de vlp.
JOP20210051A1 (ar) علاج للسرطان بواسطة استخدم توليفة من فيروس الوقس الحال للورم ومثبط نقاط الفحص المناعي، وتركيبة صيدلانية ودواء توليفي للاستخدام في علاج السرطان
BR112018072372A2 (pt) combinações de vacina terapêutica contra o hpv
CO2018009205A2 (es) Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
CR20220602A (es) Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus
MX2017005418A (es) Tratamiento de cancer y lesion de piel.
CO2023006083A2 (es) Composición y método para el tratamiento del cáncer utilizando una vacuna como un primer ingrediente activo terapéutico en combinación con un segundo ingrediente activo
ZA202305254B (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
MX383214B (es) COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACIÓN DE TRAUMA DE TEJIDO BLANDO.
PH12015502086A1 (en) Ablative immunotherapy
CL2023000037A1 (es) Arn terapéutico para el cáncer positivo para vph
林士敏 et al. Treatment Outcomes of Two Different Pre-Operative Modalities for Patients with Rectal Cancer: A Retrospective Study and the Importance of Major Surgery
魏少忠 Surgical Resection of Multiple Liver Metastasis of functional Malignant Pheochromocytoma: One Case Reported and literature review
HK1239539A1 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumours